Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis by Balog, Attila et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Pathobiology 2004;71:274–280 
 DOI: 10.1159/000080062 
 Investigation of the Prognostic Value of TNF- · 
Gene Polymorphism among Patients Treated 
with Infl iximab, and the Effects of Infl iximab 
Therapy on TNF- · Production and Apoptosis 
 Attila Balog a     Gergely Klausz a     János Gál d     Tamás Molnár b     Ferenc Nagy b     
Imre Ocsovszky c     Zsófi a Gyulai a     Yvette Mándi a   
 a 
  Department of Medical Microbiology and Immunobiology,  b   First Department of Internal Medicine, 
 c   Department of Biochemistry, Faculty of Medicine, University of Szeged,  Szeged ,  d   Department of 
Rheumatology, County Hospital,  Kecskemét , Hungary 
more suitable candidates for infl iximab treatment. Al-
though in vitro infl iximab treatment for 48 h resulted in 
signifi cant (44.2  8 1.17%) apoptosis in PBMCs, in ex vivo 
 samples from RA patients who received infl iximab, 
apoptosis was only 13.3  8 1.6%. Furthermore, infl iximab 
did not result in irreversible inhibition of the TNF- · -pro-
ducing ability or in the signifi cant apoptosis of PBMCs. 
 Copyright © 2004 S. Karger AG, Basel 
 Introduction 
 The central role of tumor necrosis factor- · (TNF- · ) in 
the pathogenesis of rheumatoid arthritis (RA) and Crohn’s 
disease (CD) has been well documented  [1, 2] , and 
 TNF- · is therefore an excellent therapeutic target. One 
of the most effective biological agents, inﬂ iximab, a chi-
meric anti-TNF antibody, has been shown to be highly 
effective for the treatment of both patients with CD  [3] 
and patients with RA  [4, 5] . The experiments reported 
here focus on patients with active RA in whom tradition-
al treatment with disease-modifying antirheumatic drugs 
had not been successful, and on patients with steroid-re-
fractory CD. All of these patients underwent inﬂ iximab 
therapy. Despite the generally dramatic efﬁ cacy of inﬂ ix-
imab, some of our patients did not display a clinical re-
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 Abstract 
 Objectives: Infl iximab, a chimeric anti-tumor necrosis 
factor (TNF) antibody, is highly effective for the treat-
ment of Crohn’s disease (CD) and rheumatoid arthritis 
(RA). Our experiments focused on RA and CD patients 
receiving infl iximab. Since cytokine production is large-
ly determined by genetic factors, the promoter polymor-
phisms of TNF- · were examined among these patients. 
Additionally, the changes caused by infl iximab in the 
TNF- · -producing ability and apoptosis of peripheral 
blood mononuclear cells (PBMCs) were investigated. 
 Methods: The TNF- · genotypes were analyzed by PCR-
RFLP. The in vitro  TNF- · production of the PBMCs was 
detected by fl ow cytometric analysis. The TNF- · concen-
tration in the supernatant was measured by bioassay. 
Apoptosis was detected by annexin V-fl uorescein iso-
thiocyanate labeling.  Results and Conclusions: 8 of the 
12 nonresponder patients carried the TNF A allele associ-
ated with high TNF- · production. We suggest that the de-
termination of TNF polymorphism may help identify 
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sponse. We hypothesized that a genetic predisposition 
might be involved in the level of responsiveness. Since 
cytokine production is largely determined by the poly-
morphism of regions regulating cytokine expression, the 
most frequently investigated promoter polymorphism at 
the –308 position of TNF- ·  [6] was examined among RA 
and CD patients receiving inﬂ iximab therapy. The less 
frequent TNF A allele of the –308 TNF- · gene polymor-
phism has been associated with increased TNF transcrip-
tion and production  [7–9] and with more severe, either 
steroid-dependent or ﬁ stulizing CD  [10] . We therefore set 
out to investigate the possible association between the –
308 TNF- · genotype and the response to inﬂ iximab. 
 An effective host response depends in part on the cy-
tokine-producing ability, including TNF- ·  [11] . Since 
there have been reports of adverse events with TNF in-
hibitors, including infections and cases of sepsis  [11–13] , 
and since the mechanism of action of inﬂ iximab is only 
partly understood  [5, 14, 15] , the changes caused by in-
ﬂ iximab in the TNF- · -producing ability of peripheral 
blood mononuclear cells (PBMCs) were investigated, to-
gether with apoptosis in PBMCs. 
 Patients and Methods 
 Patients 
 Nine patients with disease-modifying antirheumatic drug-re-
fractory RA were diagnosed according to the revised 1987 Ameri-
can College of Rheumatology criteria  [16] . The infusion regimen 
was as follows: 3 mg/kg inﬂ iximab (Schering-Plough) administered 
at 0, 2 and 6 weeks and then every 8 weeks for 1 year. 
 The 14 patients with chronic active CD unresponsive to stan-
dard therapy were diagnosed in accordance with clinical guidelines 
and on the basis of conventional radiological, endoscopic and his-
topathologic examinations  [17] . Fistulas were a common complica-
tion. The infusion regimen was as follows: 5 mg/kg inﬂ iximab ad-
ministered at 0, 2 and 6 weeks. 
 All patients underwent regular control examinations. All pa-
tients and controls were adults of Hungarian ethnic origin and re-
sided in Hungary. 
 Following the inﬂ iximab therapy, the RA patients were divided 
into responding and nonresponding groups according to the follow-
ing parameters: the DAS-28 (disease activity score), a health assess-
ment questionnaire, a pain visual analog score, the swollen and 
tender joint index, morning stiffness, the C-reactive protein level, 
the erythrocyte sedimentation rate, the physician’s global assess-
ment, the patient’s global assessment, and the American College of 
Rheumatology functional capacity score. After treatment with in-
ﬂ iximab, the CD patients were categorized as responders if steroid 
therapy could be stopped, if there were no draining ﬁ stulas or most 
of the ﬁ stulas had closed, and if the number of liquid or very soft 
stools had decreased markedly. 
 This study was performed in accordance with the ethical stan-
dards laid down in the most recent version of the 1964 Declaration 
of Helsinki. The ethical committee of the participating university 
approved the study. Informed written consent was obtained in ad-
vance from each patient. 
 DNA Extraction 
 Genomic DNA from whole blood containing EDTA was ex-
tracted using standard techniques (High Pure PCR Template Prep-
aration Kit, Roche, catalog No. 1796828). 
 –308 TNF- · Genotyping 
 The G to A transition at position –308 in the promoter region 
is associated with elevated expression of TNF- · . Using the method 
described by Wilson et al.  [18] , a PCR was followed by digestion 
with the endonuclease  Nco I. Upon analysis by acrylamide gel elec-
trophoresis, the TNF G allele gives two fragments of 87 and 20 bp, 
while the TNF A allele gives a single, 107-bp fragment. A total of 
9 patients with RA and 14 with CD as well as 75 healthy blood do-
nors were analyzed. 
 Detection of TNF- · in Supernatant of Whole Blood Cultures 
 TNF- · concentrations in the supernatants of whole blood cul-
ture (WBC) samples of the 9 patients with RA were determined by 
bioassay, applying the WEHI 164 mouse ﬁ broblast cell line  [19] . 
Human recombinant TNF- · (Amersham) was used as a standard in 
the same assay. The speciﬁ city  of the effect of TNF- · in the super-
natants was conﬁ rmed via the neutralizing effect of monoclonal 
anti-TNF- · antibody, clone TA-31 (Sigma product No. T1549). The 
amounts of TNF- · are expressed in U/ml. In control experiments, 
TNF- · concentrations in the supernatants of WBC samples were 
also determined using a TNF- · ELISA kit (Biosource), according to 
the instructions of the manufacturer. For comparison, the amounts 
of TNF- · determined in the two assays are expressed in U/ml, where 
1 unit is equivalent to 34 pg of recombinant human TNF- · . 
 Isolation of Human Mononuclear Cells 
 Peripheral white blood cells were prepared by density gradient 
puriﬁ cation (Ficoll-Paque, Sigma) from heparinized venous blood 
samples from healthy volunteers and from RA patients treated with 
inﬂ iximab, and 95% cell viability was then conﬁ rmed by trypan 
blue staining. Subsequently, 5  ! 10 6 /ml PBMCs suspended in me-
dium were used in all the experiments. Isolated cells were incu-
bated in RPMI-1640 medium (Gibco) supplemented with 10% fe-
tal bovine serum, antibiotics and glutamine. 
 Intracellular Staining of TNF- · 
 PBMCs were incubated in RPMI-1640 medium (Gibco) supple-
mented with 10% fetal bovine serum, antibiotics and glutamine for 
24 or 48 h in the presence or absence of inﬂ iximab (100  Ì g/ml). Af-
ter centrifugation, the cells were washed with phosphate-buffered 
saline (PBS). They were then stimulated with heat-killed (90 °  C for 
10 min adjusted to 10 8 /ml)  [20]  Staphylococcus aureus (SA) as TNF 
inducer in the presence of brefeldin A (10  Ì g/ml) for 4 h at 37 °  C in 
a humidiﬁ ed 5% CO 2  incubator. After centrifugation, the cells were 
washed with PBS and permeabilized with Cytoﬁ x-Cytoperm solu-
tion (Becton-Dickinson) for 20 min at room temperature in the 
dark. Thereafter, they were washed twice with PermWash (Becton-
Dickinson) solution and once with added ﬂ uorescein isothiocyanate 
(FITC)-labeled human TNF- · speciﬁ c monoclonal antibodies 
(MAbs) for 30 min at room temperature in the dark. They were next 
washed twice with PermWash and once with added PBS. Flow cy-
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tometric analysis was subsequently performed with a FACStar plus 
ﬂ uorescence-activated cell sorter (Becton-Dickinson) at 488-nm ex-
citation to estimate intracellular TNF- · in the peripheral mono-
nuclear cells. Cells were gated for CD14-positive cells as follows. 
CD14 expression was detected with phycoerythrin-conjugated 
MAbs. At the same time, a dot plot display was used to identify 
monocytes, which correlated with the gate applied for CD14-posi-
tive cells. In subsequent experiments, this gate was applied. 
 Detection of Apoptosis with Annexin V 
 Cell apoptosis was assessed by annexin V-FITC staining with a 
ﬂ ow cytometric apoptosis detection kit (PharMingen, Becton-Dick-
inson, catalog No. 556420). 
 The PBMCs were incubated for 24–48 h in the presence or ab-
sence of inﬂ iximab (100  Ì g/ml), then washed twice in PBS and re-
suspended in binding buffer (0.1  M Hepes-NaOH, 1.4  M NaCl, 
 25 m M CaCl 2 ) at a concentration of 1  ! 10 6  cells/ml. 5  Ì l of an-
nexin V-FITC and 10  Ì l of propidium iodide (PI) were added to a 
100- Ì l aliquot of each cell solution. This was followed by gentle 
mixing and incubation for 15 min at room temperature in the dark. 
Next, 400  Ì l of binding buffer was added to each tube. Flow cyto-
metric analysis was performed within 30 min. 
 Those cells that were negative for both dyes were considered to 
be live cells; necrotic cells were positive for both ﬂ uorochromes or 
only for PI, and apoptotic cells were positive only for annexin V-
FITC and negative for PI. 
 Statistical Analysis 
 The levels of intracellular TNF- · production with the SA in-
ducer and the experimental results for apoptosis were compared by 
means of one-way ANOVA. The Student-Newman-Keuls test was 
used for post hoc pairwise multiple comparisons. In all tests, an  · 
level of p  ! 0.05 was taken as an indication of statistical signiﬁ cance. 
All statistical calculations were performed with the GraphPad 
Prism4 statistical program. 
 Results 
 TNF- · Polymorphism in Patients Treated with 
Inﬂ iximab 
 Table 1 shows genotypes for –308 TNF- · in patients 
receiving inﬂ iximab and in the control group. The frequen-
cy of TNF A (which is associated with high TNF- · produc-
tion) carriers was 32% in healthy blood donors from among 
the South Hungarian population (24 of 75), which was 
similar to previously reported data  [21] . The frequency of 
TNF A carriers in the patient group was higher, i.e. 39.1% 
(9 of 23). Almost all of these 9 patients (8/9) were nonre-
sponders (4 RA and 4 CD nonresponder patients). Eight 
of the 12 nonresponder CD or RA patients carried the 
TNF A allele (66.6%). Statistical analysis was not applied 
because of the relatively small number of patients receiv-
ing inﬂ iximab therapy. However, the high number of TNF 
A carriers in the nonresponding group is very striking. 
 Effect of Inﬂ iximab Therapy on in vitro TNF- · 
Production by WBCs 
 The in vitro  TNF- · production by WBCs was deter-
mined at different times after inﬂ iximab therapy. The 
TNF- · concentration in the supernatants of the WBCs 
before inﬂ iximab treatment was considerable (527.8  8 
363.2 U/ml;  ﬁ g. 1 ). It is noteworthy that those patients 
who carried the TNF A allele exhibited the highest in vi-
tro  TNF production (data not shown). 
 After the 3rd infusion of inﬂ iximab, the in vitro 
 TNF- · production was only 33.0  8 12.2 U/ml, and after 
the 4th infusion, it was below the detection limit of the 
 Table 1. TNF- · genotypes in patients receiving inﬂ iximab therapy 
and in control subjects 
Group TNF G/
TNF G
TNF G/
TNF A
TNF A/
TNF A
Patients treated with inﬂ iximab (n = 23)
Responders 10 11 0
Nonresponders 14 18 0
Healthy controls (n = 75) 51 22 2
The variations in the TNF-· genotypes were analyzed by PCR-
RFLP, using the NcoI restriction enzyme, in 23 patients (9 with RA, 
14 with CD) treated with inﬂ iximab and 75 age- and sex-matched 
healthy blood donors from the South Hungarian population.
 Fig. 1. TNF- · concentration in supernatants of whole blood sam-
ples from 9 RA patients treated with inﬂ iximab following heat-
killed SA stimulation of the cells. A: Before inﬂ iximab therapy; B: 
48 h after the 3rd infusion; C: 48 h after the 4th infusion; D: 48 h 
after the 4th infusion – inﬂ iximab was washed out from the whole 
blood cells. Data are means  8 SEM. 
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assay. When we washed out the inﬂ iximab from the WBCs 
(two washings at 1,500 rpm for 5 min with PBS, followed 
by resuspension in RPMI-1640 supplemented with 10% 
FCS), a marked TNF- · concentration of 319.4  8 
 141.3 U/ml was measured even after the 4th infusion. It 
is very likely that the anti-TNF antibody in the superna-
tants of the WBCs could neutralize the cytotoxic effect of 
TNF- · . The reduced TNF could simply be due to TNF- · 
trapping by inﬂ iximab, which means it is then not recog-
nized either by bioassay or by ELISA. 
 Effect of Inﬂ iximab on Intracellular TNF- · Content 
of Monocytes 
 Following SA stimulation, the in vitro TNF- · produc-
tion by monocytes from the healthy controls was in-
creased signiﬁ cantly, as revealed by an intracellular TNF-
 · staining method.  Figure 2 depicts representative ex-
periments on the detection of the intracellular TNF- · 
content in human monocytes. 
 Pretreatment of mononuclear cells with 100  Ì g/ml in-
ﬂ iximab for 24 or 48 h did not result in a loss of their 
TNF-producing ability; the mean ﬂ uorescence intensity 
data for the control and SA-stimulated cells were signiﬁ -
cantly different in each experiment, as assessed by the 
ANOVA test ( ﬁ g. 3 ). The same tendency was observed for 
the mononuclear cells of the RA patients 48 h after the 
4th infusion of inﬂ iximab: F(7,28) = 65.89, p  ! 0.001 ( ﬁ g. 
3 ). Accordingly, we conclude that the inﬂ iximab therapy 
did not inhibit the ability of these cells to respond to the 
bacterial inducer with TNF- · production. 
0
10
20
30
40
50
C
o
u
n
ts
M1
100 101 102 103 104
Mononuclear cells
without SA stimulation
FL1-Height
20
0
10
30
40
50
C
o
u
n
ts
M1
100 101 102 103 104
Mononuclear cells
stimulated with SA for 4 h
FL1-Height
 Fig. 2. Flow cytometric analysis of the in-
tracellular TNF- · content in human mono-
cytes. The basal and heat-killed SA-stimu-
lated cytokine responses of the monocytes 
were determined. Monocytes were gated for 
CD14-positive cells. Intracellular TNF- · 
expression was detected via the staining of 
permeabilized cells with FITC-conjugated 
MAbs speciﬁ c for human TNF- · , and mea-
sured by ﬂ ow cytometric analysis. M1 = 
Fluorescence intensity in monocytes. 
 Fig. 3. Intracellular TNF- · production in monocytes of healthy 
blood donors following in vitro inﬂ iximab treatment (A–C) and in 
monocytes of patients receiving inﬂ iximab therapy (D). The intra-
cellular TNF- · content of the cells (10 5  in each sample), expressed 
as mean ﬂ uorescence intensity, was measured by ﬂ ow cytometric 
analysis of permeabilized cells stained with FITC-conjugated hu-
man speciﬁ c MAbs against TNF- · , and gated for monocytes. A: 
Mononuclear cells from healthy blood donors (n = 4) with (ﬁ lled 
bars) or without (open bars) heat-killed SA stimulation; B: mono-
nuclear cells from healthy blood donors (n = 4), cultivated for 48 h, 
and thereafter incubated with (ﬁ lled bars) or without (open bars) 
SA; C: mononuclear cells from healthy blood donors (n = 4), pre-
treated in vitro  with inﬂ iximab for 48 h, and thereafter incubated 
with (ﬁ lled bars) or without (open bars) SA; D: mononuclear cells 
from patients with RA (n = 6) were isolated 48 h after the 4th infu-
sion with inﬂ iximab, and incubated for a further 4 h with (ﬁ lled 
bars) or without (open bars) SA. In each group, a signiﬁ cant differ-
ence was observed between the stimulated and nonstimulated sub-
groups [F(7,28) = 65.89, p  ! 0.001]. 
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 Effect of Inﬂ iximab on Apoptosis of PBMCs 
 The effect of inﬂ iximab on the apoptosis of PBMCs 
was investigated at different time points following the in 
vitro inﬂ iximab pretreatment of PBMCs from the healthy 
blood donors. The results were compared with the apop-
tosis of PBMCs isolated from the patients receiving in-
ﬂ iximab therapy 48 h after the 4th infusion.  Figure 4 
shows a representative experiment for the detection of 
apoptosis of the PBMCs of a healthy blood donor; in vitro 
inﬂ iximab treatment (100  Ì g/ml) of the PBMCs for 48 h 
resulted in an increase in the percentage of apoptotic cells 
(25.46 vs. 44.23%). The kinetic study revealed that spon-
taneous apoptosis was slightly elevated following a 48-
hour incubation of the PBMCs ( ﬁ g. 5 ), but it was not sig-
niﬁ cant according to the ANOVA test. There was a sig-
niﬁ cant increase in apoptosis, however, as a result of a 
48-hour in vitro treatment of the PBMCs with inﬂ iximab 
[ ﬁ g. 5 , bar D; F(4,17) = 83.53, p  ! 0.001]. In comparison 
with this in vitro inﬂ iximab treatment, in ex vivo  samples 
investigated directly from the RA patients undergoing 
inﬂ iximab therapy, the degree of apoptosis was not con-
siderable ( ﬁ g. 5 , bar E). Hence, we conclude that this in-
ﬂ iximab therapy itself did not result in as high a rate of 
apoptosis as was observed with the in vitro treatment of 
PBMCs for 48 h. 
 Discussion 
 The clinical efﬁ cacy of the biological response modiﬁ er 
inﬂ iximab proved to be impressive. One of the crucial 
questions that arises is how to select the optimal rate of 
TNF inhibition for each patient  [22] . The degree of TNF 
inhibition required to control the disease in an optimal 
manner may vary from patient to patient. It may depend 
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 Fig. 5. Comparison of in vitro and in vivo effects of inﬂ iximab on 
the apoptosis of PBMCs. The percentage of apoptotic cells was de-
termined by annexin V-FITC labeling. A: Untreated PBMCs from 
healthy blood donors (n = 4) after a 24-hour incubation; B: PBMCs 
from healthy blood donors (n = 4) treated in vitro with inﬂ iximab 
(100  Ì g/ml) for 24 h; C: untreated PBMCs from healthy blood do-
nors (n = 4) after a 48-hour incubation; D: PBMCs from healthy 
blood donors (n = 4) treated in vitro with inﬂ iximab (100  Ì g/ml) for 
48 h; E: PBMCs from RA patients (n = 6) 48 h after the 4th infusion 
with inﬂ iximab. Data are means  8 SEM. * Signiﬁ cantly higher 
number of apoptotic cells in D [F(4,17) = 83.53, p  ! 0.001]. 
 Fig. 4. Effect of in vitro  inﬂ iximab treat-
ment on the apoptosis of PBMCs. PBMCs 
were labeled with annexin V-FITC and PI. 
Surviving cells (low signals for both annex-
in V and PI) appear in the lower-left quad-
rant, early apoptotic cells (high annexin V 
signal, but low PI signal) in the lower-right 
quadrant, and necrotic cells (high signals 
for both annexin V and PI) in the upper-
right and upper-left quadrants. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f S
ze
ge
d 
   
   
   
   
   
   
   
   
   
   
   
 
16
0.
11
4.
15
0.
95
 - 
7/
2/
20
19
 1
0:
39
:5
7 
AM
 Inﬂ iximab Therapy, TNF- · Gene 
 Polymorphism and TNF- · Production 
 Pathobiology 2004;71:274–280 279
on the patient’s weight or the drug metabolism, but also 
on each patient’s innate TNF production. We should learn 
to titrate our therapy so as to achieve a level of TNF inhi-
bition that counters the disease, but without crippling im-
portant immune functions. Determination of the optimal 
degree of TNF inhibition that is safe and effective in each 
patient is crucial. We hypothesized that the therapeutic 
response of patients treated with inﬂ iximab might be re-
lated to the genetic propensity of the host to produce high 
levels of TNF- · . Knowledge of the TNF- · gene polymor-
phism in all patients treated with inﬂ iximab may result in 
a better understanding of how to optimize TNF inhibition 
in individual patients. It is possible that a higher dose of 
inﬂ iximab is necessary for optimal TNF inhibition in 
TNF A carriers, as this allele is associated with a higher 
TNF- · -producing ability  [7, 8] . An increased frequency of 
the TNF A allele has been found among nonresponder RA 
patients receiving inﬂ iximab  [23] . In contrast, there was 
no relevant association between the –308 TNF gene poly-
morphism and the clinical response to inﬂ iximab in the 
study of Louis et al.  [24] in CD patients. In another study, 
a rather small cohort of patients did display an association 
between polymorphisms in the lymphotoxin A gene and 
the response to inﬂ iximab  [25] . These results, and also 
those of our own investigation, should be conﬁ rmed in 
larger populations of patients. Our pilot study draws at-
tention to the connection between the therapeutic re-
sponse to inﬂ iximab and the –308 TNF- · gene polymor-
phism in RA and CD patients. There was a strong ten-
dency for a much higher frequency of carriers of the TNF 
A allele among nonresponders ( table 1 ). 
 The low number of patients in our study group is due 
to the high costs of inﬂ iximab therapy. A much larger set 
of patients on inﬂ iximab therapy will be necessary in the 
future for a reliable statistical analysis in order to conﬁ rm 
our preliminary results. 
 Another important feature of our study is the demon-
stration that the cytokine-producing ability of PBMCs is 
not irreversibly impaired by inﬂ iximab therapy, as re-
vealed by ex vivo experiments in which washed WBCs 
were used ( ﬁ g. 1 ). Stimulation of these white blood cells 
with killed SA led to TNF- · production, which could be 
detected in a bioassay when the anti-TNF antibodies were 
washed out in the supernatant of the cell cultures. The 
retained TNF- · -producing ability was further proved in 
experiments in which intracellular TNF- · was detected 
in monocytes. 
 TNF- · plays an important part in the pathomechanism 
of both RA and CD  [1, 2] . Additionally, it has a central 
role in the immune system, is an important mediator of 
local inﬂ ammation and appears to be vital in keeping in-
fections localized. Infections and cases of sepsis have been 
reported in patients receiving inﬂ iximab  [12, 13] . Tuber-
culosis seems to be particularly common  [11] . An effective 
host response depends partly on the ability to produce an 
appropriate Th1 cytokine proﬁ le, including TNF- · , which 
is involved in protection against both mycobacterial infec-
tion and pathogenesis of tuberculosis  [26] . We have dem-
onstrated that the neutralizing effect of anti-TNF therapy 
does not result in irreversible inhibition of the TNF- · -
producing ability of mononuclear cells. 
 Monocytopenia is commonly observed after treatment 
with inﬂ iximab. Treatment with inﬂ iximab at therapeutic 
concentrations resulted in apoptosis of monocytes in pa-
tients with chronic active CD who were receiving a dose 
of  6 5 mg/kg  [27] . We investigated the role of inﬂ iximab-
induced apoptosis of PBMCs in RA patients receiving 
3 mg/kg inﬂ iximab. In our in vitro experiments, a 48-hour 
treatment of PBMCs with inﬂ iximab resulted in a signiﬁ -
cant increase in the level of apoptosis ( ﬁ g. 4 ). However, 
signiﬁ cant apoptosis was not observed in a direct analysis 
of the PBMCs of RA patients treated with inﬂ iximab. 
 In our experiments, we investigated the effects of in-
ﬂ iximab on the TNF- · production and apoptosis of 
PBMCs in vitro and in vivo, together with the possible 
clinical relevance of the –308 TNF- · polymorphism in 
inﬂ iximab therapy of RA and CD patients. 
 Treatment of TNF inhibitors may be accompanied by 
adverse events, and the precise mechanism of the inﬂ ix-
imab therapy remains unclear. In our study, the poten-
tially TNF- · -producing PBMCs retained their host de-
fense function and their number was not decreased sta-
tistically by apoptosis. Monocytopenia/leukopenia was 
not observed in either our RA patients or our CD pa-
tients. These investigations may promote a better under-
standing of the effects of inﬂ iximab. It is important to 
stress that a rigorous follow-up of patients receiving in-
ﬂ iximab is essential, however, in order for possible toxic 
effects and infections to be recognized in time, so that 
alternative medication can be applied  [22] . 
 In view of the high costs of inﬂ iximab therapy, it ap-
pears necessary to determine the TNF genotype before 
such therapy is initiated, so as to achieve a better progno-
sis. 
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